ADT + darolutamide + docetaxel (ARASENS triplet)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-LEUPROLIDE` `DRUG-DAROLUTAMIDE` `DRUG-DOCETAXEL`

ID	`REG-ADT-DAROLUTAMIDE-DOCETAXEL`
Type	Regimen
Status	pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ESMO-PROSTATE-2024` `SRC-NCCN-PROSTATE-2025`

Notes

ARASENS: significant OS benefit for triplet vs ADT + docetaxel in high-volume mHSPC. Requires docetaxel-eligible patient (ECOG 0-1, no significant comorbidity). UA-access constrained by darolutamide reimbursement gap — flagged for clinical-review queue.

Used By

Handbook Chapters

HB-PROSTATE-MCRPC-1L - Metastatic castration-resistant prostate cancer: biomarker and sequencing reasoning

Indication

IND-PROSTATE-MHSPC-1L-TRIPLET - IND-PROSTATE-MHSPC-1L-TRIPLET